![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, May 27, 2005 12:30:27 PM
Frog commented on Bag8gers assunption that something big might be in the offing. Frog noted that all the company has said is we need more shares. Frog stated that the purpose of the "shares" is more dillution. I feel Frog is being shortsighted when he states the only purpose is "more dillution." The previous "dillution" was the selling of shares to provide operating funds. I consider this exercise in share consolidation as a continuation of that "funding need". There are many DNAP products in the pipeline. However Forward Looking Statements are frowned on. Would Frog prefer that DNAP say "We have a cure for cancer and just need this cash to put us over the top for expenses to market it". WE can predict that the company needs more funds to continue operation. Providence and market forces have led to this current state. Without an infusion of funds, DNAP will have to sell out. This will in effect negate any future value my shares may have held. We invested on future value, and have not realized it yet. If you believe the company has it's ducks in a row the future value is near.
If you feel the management team has misled or mis-managed, then you have based your decision to stay here on a desire to prevent the remaining shareholders from ever having any sucess. The management team is the same. The prospects have been improved by the Beth Israel patent agreement. Financing has been arranged. What is the collatteral for the financing? Shares of DNAP? Control of DNAP?
Hanging around to continue to belittle the value of DNAP, it's management and science is fine if your purpose is destruction of any remaining value. For all the tens of hundreds of posts that those "F" posters inflict on our physche, they seldom if ever, offer any constructive input. In an investment, you accept the possibility of being wrong and losing it all. Meanwhile you can gripe about the loss and offer suggestions, or even just bring to the companies attention the activities of competitors. Continued nay-saying and degrading of the character of management and the science when not backed by factual and documented impartial sources is in my view bashing.
Can we say that the failure of DNAP to have any patents issued is an impartial source of non-validation of the company and Doctor Frudakis? -- It is undecided at this time. We knew going in that the patent procedure would be lenghty because the "patents applied for" where quite novel and the Patent Office often has to rely on both it's internal and some external sources for review of such new and leading edge procedures. The decision isn't in yet. DNAP hasn't been rebuffed and I believe most of the patents applied for are still in the review process.
DNAP's future is still an open book. I can't prognosticate if the issuance of a patent is right around the corner. I also can't prognosticate if the all the applications will be denied. (What if they were denied because the Patent Office couldn't understand them, or felt political pressure not to rock the racial boat)? This would not prevent DNAP from using the procesures and markers to further it's work in personalized medicine. It would hurt. But as long as Doctor Frudakis is willing to apply his life and resources to DNAP, I will try to do my best to see him through the fray.
I still take exception to posters who's only reason for posting is to make sure they shovel the last spadeful on the grave. It would be nice to see an occassional variance from the dance of the macabre but I'm afraid the inate inability to look for good is a characteristic of the breed. Must be in the DNA.
Stakddek
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM